Stock 002793 LUOXIN PHARMACEUTICALS GROUP STOCK CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Luoxin Pharmaceuticals Group Stock Co., Ltd.

Equities

002793

CNE1000026S7

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 27/05/2024 BST 		5-day change 1st Jan Change
4.97 CNY -3.87% Intraday chart for Luoxin Pharmaceuticals Group Stock Co., Ltd. -1.97% -7.28%
04-26 Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-08 Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology
MT
Tranche Update on Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback Plan announced on February 2, 2024.
CI
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback announced on February 2, 2024, has closed with 26,027,861 shares, representing 2.39% for CNY 99.99 million.
CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.
CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. authorizes a Buyback Plan.
CI
Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial
MT
Two Luoxin Pharma Drugs Selected in China’s National Drug Procurement Program
MT
Luoxin Health Technology Development Co., Ltd. announced that it has received CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.
CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s LX-039 (Innovative Anti-Tumor Drug) Phase I Clinical Study Data Presented At ESMO 2023
CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. agreed to acquire additional unknown stake in Luoxin Health Technology Development Co., Ltd. from Chengdu Deyi Xinhua Equity Investment Partnership Enterprise (LP) and Deyi Investment Management Co., Ltd. for CNY 1.
CI
Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.
CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Elects Li Meng as Non-Independent Directors
CI
Luoxin Pharmaceuticals' Injection Passes Regulatory Consistency Evaluation
MT
Luoxin Pharmaceuticals Gets Regulatory Nod for Anti-Baterial Infection Drug
MT
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002793 Stock
  4. News Luoxin Pharmaceuticals Group Stock Co., Ltd.